EPZM - エピザイム (Epizyme Inc.) エピザイム

 EPZMのチャート


 EPZMの企業情報

symbol EPZM
会社名 Epizyme Inc. (エピザイム)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エピザイム(Epizyme Inc.)は臨床段階のバイオ医薬品会社である。同社はがん患者向けエピジェネティック治療法の発見・開発・商品化する計画を行う。同社は、がん患者向け新規エピジェネティック治療法の発見・開発に従事する。同社はヒストンメチルトランスフェラーゼ(HMT)として知られる各種酵素小分子阻害剤を開発する。同社は他のクロマチン修飾タンパク質(CMP)の小分子阻害剤を開発する。同社のリード製品候補であるタゼメトスタットは、各種がんにおいて役割を果たす酵素であるゼスト相同体2(EZH2)ヒストンメチルトランスフェラーゼ(HMT)のエンハンサーの選択的阻害剤である。同社は再発性または難治性の非ホジキンリンパ腫(NHL)を有する成人第II相試験及び分子標的腫瘍を有する小児の第I相試験でタゼメトスタットを評価する。同社は日本以外のタゼメトスタットに対する世界的開発・商業化権利を有する。   エピザイムは、米国のバイオ医薬品企業。遺伝によるがん患者向けに個別の治療薬の開発、商品化を行う。ヒストンメチルトランスフェラ―ゼとして知られる酵素の阻害剤作成用に独自の製品プラットフォ―ムを開発。遺伝子変異を持つ急性白血病や、遺伝による非ホジキンリンパ腫および固形腫瘍の治療薬の開発を手掛ける。本社はマサチュ―セッツ州ケンブリッジ。  Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
本社所在地 400 Technology Square Cambridge MA 02139 USA
代表者氏名 David M. Mott デビッド・モット
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-229-5872
設立年月日 39387
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 131人
url www.epizyme.com
nasdaq_url https://www.nasdaq.com/symbol/epzm
adr_tso
EBITDA EBITDA(百万ドル) -139.26100
終値(lastsale) 9.23
時価総額(marketcap) 641865774.42
時価総額 時価総額(百万ドル) 737.47240
売上高 売上高(百万ドル) 12.00000
企業価値(EV) 企業価値(EV)(百万ドル) 521.91640
当期純利益 当期純利益(百万ドル) -136.95600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Epizyme Inc revenues increased 20% to $12M. Net loss increased 4% to $63.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 11% to $54.6M (expense) Stock-based Compensation in SGA increase of 38% to $4M (expense) Other income decrease of 50% to $7K (income).

 EPZMのテクニカル分析


 EPZMのニュース

   Epizyme Q1 2022 Earnings Preview  2022/05/09 16:10:33 Seeking Alpha
Epizyme (EPZM) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open.The consensus EPS Estimate is -$0.35 (+49.3% Y/Y) and the consensus Revenue Estimate…
   Epizyme Announces Date of First Quarter 2022 Financial Results  2022/05/03 11:00:00 Business Wire
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer
   Analysts Predict Epizyme Inc. (NASDAQ: EPZM) To Loss -1288.89% From Current Levels.  2022/04/19 15:00:00 Stocks Register
The trading price of Epizyme Inc. (NASDAQ:EPZM) closed lower on Monday, April 18, closing at $0.72, -6.03% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7048 and … Analysts Predict Epizyme Inc. (NASDAQ: EPZM) To Loss -1288.89% From Current Levels. Read More »
   Epizyme Inc. (NASDAQ: EPZM): Stock Plunge On The Way?  2022/04/18 14:00:00 Stocks Register
The trading price of Epizyme Inc. (NASDAQ:EPZM) closed lower on Thursday, April 14, closing at $0.76, -6.35% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7352 and … Epizyme Inc. (NASDAQ: EPZM): Stock Plunge On The Way? Read More »
   Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer  2022/04/18 13:00:00 Kwhen Finance
   64 Biggest Movers From Yesterday  2022/01/28 09:59:13 Benzinga
Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human Imaging Limited (NASDAQ: AHI ) fell 33.8% to settle at $1.82. Advanced Human Imaging recently signed partnership with Activate Health OÜ. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) dropped 33.6% to close at $0.6280.
   Why Epizyme Stock Plummeted by 44% Today  2022/01/27 23:27:17 The Motley Fool
News of a dilutive share issue left investors feeling queasy.
   Aridis, Galapagos lead healthcare gainers; Epizyme, Cue Biopharma among losers  2022/01/27 15:03:00 Seeking Alpha
Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.
   Epizyme jumps after product revenue shows strong sequential growth: Q4 Prelim  2022/01/10 16:55:28 Seeking Alpha
Epizyme <> reports its preliminary estimate for TAZVERIK product revenue to be $11.2-$11.7M for Q4 2021. TAZVERIK commercial sales is expected to be between $7.0-7.5M, representing…
   Epizyme Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover  2021/12/30 03:18:32 Kwhen Finance
Epizyme Inc (EPZM) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $270M. The stock is currently down 76.1% year-to-date, down 77.9% over the past 12 months, and down 78.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 57.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -690.1% The company's stock price performance over the past 12 months lags the peer average by -739.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Epizyme jumps after product revenue shows strong sequential growth: Q4 Prelim  2022/01/10 16:55:28 Seeking Alpha
Epizyme <> reports its preliminary estimate for TAZVERIK product revenue to be $11.2-$11.7M for Q4 2021. TAZVERIK commercial sales is expected to be between $7.0-7.5M, representing…
   Epizyme Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover  2021/12/30 03:18:32 Kwhen Finance
Epizyme Inc (EPZM) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $270M. The stock is currently down 76.1% year-to-date, down 77.9% over the past 12 months, and down 78.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 57.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -690.1% The company's stock price performance over the past 12 months lags the peer average by -739.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Invesco Ltd. Has $533,000 Stake in Epizyme, Inc. (NASDAQ:EPZM)  2021/12/14 09:10:46 ETF Daily News
Invesco Ltd. increased its position in shares of Epizyme, Inc. (NASDAQ:EPZM) by 21.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,112 shares of the biopharmaceutical company’s stock after purchasing an additional 11,536 shares during the period. Invesco Ltd. owned […] The post Invesco Ltd. Has $533,000 Stake in Epizyme, Inc. (NASDAQ:EPZM) appeared first on ETF Daily News .
   Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting  2021/12/12 14:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory study evaluating the investigational use of TAZVERIK® (tazemetostat), a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide (R2) in pati
   Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Companys SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting  2021/12/11 14:00:00 Wallstreet:Online
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today shared preclinical data and the Phase 1/1b trial design for EZM0414, the Companys novel, first-in-class, oral SETD2 inhibitor, an investigational agent being developed for the treatment of adult patients with relapsed

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エピザイム EPZM Epizyme Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)